Silverleafe Capital Partners, LLC Arcutis Biotherapeutics, Inc. Transaction History
Silverleafe Capital Partners, LLC
- $305 Million
- Q3 2025
A detailed history of Silverleafe Capital Partners, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Silverleafe Capital Partners, LLC holds 16,628 shares of ARQT stock, worth $415,700. This represents 0.1% of its overall portfolio holdings.
Number of Shares
16,628
Previous 14,500
14.68%
Holding current value
$415,700
Previous $203,000
54.19%
% of portfolio
0.1%
Previous 0.07%
Shares
3 transactions
Others Institutions Holding ARQT
# of Institutions
252Shares Held
127MCall Options Held
404KPut Options Held
133K-
Jennison Associates LLC12.3MShares$306 Million0.14% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$269 Million3.33% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.5MShares$262 Million5.93% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$247 Million7.87% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$216 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.5B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...